| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6461605 | MERCK SHARP DOHME | Continuous low-dose cytokine infusion therapy |
Nov, 2016
(7 years ago) | |
| US6177074 | MERCK SHARP DOHME | Polyethylene glycol modified interferon therapy |
Nov, 2016
(7 years ago) | |
| US6524570 | MERCK SHARP DOHME | Polyethylene glycol modified interferon therapy |
Nov, 2016
(7 years ago) | |
|
US6461605 (Pediatric) | MERCK SHARP DOHME | Continuous low-dose cytokine infusion therapy |
May, 2017
(6 years ago) | |
|
US6524570 (Pediatric) | MERCK SHARP DOHME | Polyethylene glycol modified interferon therapy |
May, 2017
(6 years ago) | |
|
US6177074 (Pediatric) | MERCK SHARP DOHME | Polyethylene glycol modified interferon therapy |
May, 2017
(6 years ago) | |
| US6472373 | MERCK SHARP DOHME | Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection |
Sep, 2017
(6 years ago) | |
| US6172046 | MERCK SHARP DOHME | Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection |
Sep, 2017
(6 years ago) | |
|
US6172046 (Pediatric) | MERCK SHARP DOHME | Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection |
Mar, 2018
(6 years ago) | |
|
US6472373 (Pediatric) | MERCK SHARP DOHME | Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection |
Mar, 2018
(6 years ago) | |
Rebetol is owned by Merck Sharp Dohme.
Rebetol contains Ribavirin.
Rebetol has a total of 10 drug patents out of which 10 drug patents have expired.
Expired drug patents of Rebetol are:
- US6461605
- US6177074
- US6524570
- US6461605*PED
- US6524570*PED
- US6177074*PED
- US6472373
- US6172046
- US6172046*PED
- US6472373*PED
Rebetol was authorised for market use on 03 June, 1998.
Rebetol is available in capsule;oral dosage forms.
Rebetol can be used as method of using peg-intron/rebetol combination therapy and intron/rebetol combination therapy, method of treating hepatitis c viral infection by continuous parenteral admin interferon alpha 2-10 million iu weekly, subcutaneously, injection of polymer-interferon alpha conjugate-polymer is peg-interferon is alpha 2b, method of treating pt with chronic hepatitis c having hcv genotype 1 and viral load greater than 2 million copies/ml to eradicate detectable hcv-rna by admin combination of ribavirin and interferon alfa-2b for a least 24 weeks, method of using rebetol capsules in combination with a conjugate comprising polyethylene glycol(peg) and an alpha interferon, including, for example, peg-intron powder for injection, method of tx a pt suspected of having hepatitis c by admin, in combination, a conjugate comprising peg 12000 & interferon alfa-2b in an amt of from 0.5mcg/kg to 2mcg/kg, once weekly, and ribavirin.
The generics of Rebetol are possible to be released after 21 March, 2018.
Drugs and Companies using RIBAVIRIN ingredient
Market Authorisation Date: 03 June, 1998
Treatment: Method of treating hepatitis c viral infection by continuous parenteral admin interferon alpha 2-10 million iu weekly, subcutaneously, injection of polymer-interferon alpha conjugate-polymer is peg-in...
Dosage: CAPSULE;ORAL
REBETOL family patents
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6524570 | SCHERING | Polyethylene glycol modified interferon therapy |
Nov, 2016
(7 years ago) | |
| US6177074 | SCHERING | Polyethylene glycol modified interferon therapy |
Nov, 2016
(7 years ago) | |
| US6461605 | SCHERING | Continuous low-dose cytokine infusion therapy |
Nov, 2016
(7 years ago) | |
|
US6177074 (Pediatric) | SCHERING | Polyethylene glycol modified interferon therapy |
May, 2017
(6 years ago) | |
|
US6524570 (Pediatric) | SCHERING | Polyethylene glycol modified interferon therapy |
May, 2017
(6 years ago) | |
|
US6461605 (Pediatric) | SCHERING | Continuous low-dose cytokine infusion therapy |
May, 2017
(6 years ago) | |
| US6472373 | SCHERING | Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection |
Sep, 2017
(6 years ago) | |
| US6172046 | SCHERING | Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection |
Sep, 2017
(6 years ago) | |
|
US6172046 (Pediatric) | SCHERING | Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection |
Mar, 2018
(6 years ago) | |
|
US6472373 (Pediatric) | SCHERING | Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection |
Mar, 2018
(6 years ago) | |
| US6790837 | SCHERING | Ribavirin syrup formulations |
Apr, 2023
(1 year, 24 days ago) | |
|
US6790837 (Pediatric) | SCHERING | Ribavirin syrup formulations |
Oct, 2023
(6 months ago) | |
Rebetol is owned by Schering.
Rebetol contains Ribavirin.
Rebetol has a total of 12 drug patents out of which 12 drug patents have expired.
Expired drug patents of Rebetol are:
- US6524570
- US6177074
- US6461605
- US6177074*PED
- US6524570*PED
- US6461605*PED
- US6472373
- US6172046
- US6172046*PED
- US6472373*PED
- US6790837
- US6790837*PED
Rebetol was authorised for market use on 29 July, 2003.
Rebetol is available in solution;oral dosage forms.
Rebetol can be used as method of using ribavirin in combination with pegylated interferon alpha-2b to treat patients with chronic hepatitis c, method of using ribavirin in combination with intron a (interferon alpha-2 b recombinant) injection to treat patients with chronic hepatitis c.
The generics of Rebetol are possible to be released after 05 October, 2023.
Drugs and Companies using RIBAVIRIN ingredient
Market Authorisation Date: 29 July, 2003
Treatment: Method of using ribavirin in combination with pegylated interferon alpha-2b to treat patients with chronic hepatitis c; Method of using ribavirin in combination with intron a (interferon alpha-2 b rec...
Dosage: SOLUTION;ORAL
REBETOL family patents